Earnings Report /
Bangladesh

Beximco Pharmaceuticals: BXPHARMA Q4 FY22: Earning growth -0.1% YoY in FY22, -42.3% YoY in Q4 FY22

  • EPS in Q4 FY22 stood at BDT 1.89 against BDT 3.27 in Q4 FY21, implying a -42.3% decline.

  • In FY22, BXPHARMA reported EPS BDT 11.48 against BDT 11.49 in FY21, implying a -0.1% decline.

  • BXPHARMA declared a BDT 3.50 dividend, implying a c31% payout level in FY22.

IDLC Securities
5 November 2022
Published byIDLC Securities
  • Earning growth -0.1% YoY in FY22, -42.3% YoY in Q4 FY22. EPS in Q4 FY22 stood at BDT 1.89 against BDT 3.27 in Q4 FY21, implying a -42.3% decline. In FY22, BXPHARMA reported EPS BDT 11.48 against BDT 11.49 in FY21, implying a -0.1% decline.

  • BXPHARMA declared a BDT 3.50 dividend, implying a c31% payout level in FY22. BXPHARMA had previously declared a similar dividend per share in FY21. However, dividend payout increased by 2.65 bps from 30.46% in FY21 to 30.49% in FY22.